CATHERINE EASTER: Open Payments
NPI 1881647444 · FISHERSVILLE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,527 in 113 payments from 18 companies in 2025. Trend: 2023 $1,918 · 2024 $1,817 · 2025 $2,527
Food & beverage: $2,527
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 29 | $526 |
| ABBVIE INC. | 21 | $495 |
| GENZYME CORPORATION | 7 | $272 |
| Madrigal Pharmaceuticals | 5 | $184 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $162 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $149 |
| Ipsen Biopharmaceuticals, Inc | 6 | $146 |
| Ardelyx, Inc. | 7 | $113 |
| QOL Medical, LLC | 3 | $90 |
| Medtronic, Inc. | 2 | $82 |
Products named: TREMFYA, DUPIXENT, REZDIFFRA, SKYRIZI, RINVOQ, XIFAXAN, LINZESS, IQIRVO.
Industry payments across VA — which companies pay providers there.
